cycloplegia: Cycloplegia is paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
538 |
4. Check minimum number of eventsNone |
538 |
5. Include endpointsNone |
538 |
6. Filter based on genotype QC (FinnGen only) |
538 |
Control definitions (FinnGen only)
- Control exclude
- G6_CPETAL
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Monoplegia
based on the number of shared cases.
Similar with more cases:
- Cerebral palsy and other paralytic syndromes
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3782 | 1832 | 1917 |
| Only index persons | 3338 | 1651 | 1687 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.05 | 0.05 |
| Only index persons | 0.06 | 0.06 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 57.60 | 56.77 | 58.25 |
| Only index persons | 56.05 | 55.02 | 57.06 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 538 | 304 | 234 |
| Unadjusted period prevalence (%) | 0.10 | 0.10 | 0.10 |
| Median age at first event (years) | 57.25 | 54.08 | 61.38 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 477
- Matched controls
- 4767
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G83.1
ICD-10 Finland
Monoplegia of lower limb
4725.2
257.6
225
*
G83.2
ICD-10 Finland
Monoplegia of upper limb
+∞
206.8
183
*
G83.3
ICD-10 Finland
Monoplegia, unspecified
+∞
86.1
80
*
G81.9
ICD-10 Finland
Hemiplegia, unspecified
+∞
37.0
35
*
TAB00
NOMESCO Finland
Lumbar puncture
10.4
32.3
65
71
AA1AD
NOMESCO Finland
CT of head and brain
3.6
31.6
181
692
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
5.1
29.7
102
240
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
6.7
25.7
68
115
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
3.9
25.0
117
368
N02AX02
ATC
tramadol; systemic, rectal
2.8
24.6
259
1436
R4110
NOMESCO Finland
Physiotherapy
3.0
24.2
182
816
N03AX12
ATC
gabapentin; oral
3.6
24.1
125
427
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.8
22.7
81
195
N03AX16
ATC
pregabalin; oral
2.9
21.7
169
763
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.5
21.1
80
205
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
4.1
20.7
87
246
XF400
NOMESCO Finland
ECG with 12 standard connections
3.2
20.6
127
486
L28
ICPC
Limited function/disability (L)
3.3
19.2
111
405
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.4
18.5
71
183
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.3
18.5
58
121
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.5
17.4
173
878
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
14.0
17.2
29
22
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.0
16.8
109
428
R4120
NOMESCO Finland
Occupational therapy
4.4
16.8
63
159
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
6.3
16.6
45
78
G57.3
ICD-10 Finland
Lesion of lateral popliteal nerve
17.5
16.2
25
15
M54.5
ICD-10 Finland
Low back pain
2.4
16.1
190
1044
R20.2
ICD-10 Finland
Paraesthesia of skin
4.7
15.9
56
132
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.0
15.8
103
403
G82.2
ICD-10 Finland
Paraplegia, unspecified
+∞
15.7
15
*
R51.80
ICD-10 Finland
Headache
2.9
15.4
102
404
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.1
15.4
93
344
N03AE01
ATC
clonazepam; systemic
4.6
15.3
54
128
M03BX01
ATC
baclofen; systemic
10.6
15.2
29
29
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.6
15.0
70
215
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.8
14.3
63
184
N02AA05
ATC
oxycodone; systemic
2.9
14.1
97
390
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
4.1
14.1
56
149
M54.4
ICD-10 Finland
Lumbago with sciatica
2.7
13.9
105
446
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
21.9
13.4
19
9
R1250
NOMESCO Finland
Evaluation of functional capability
8.9
12.9
27
32
R56.8
ICD-10 Finland
Other and unspecified convulsions
4.6
12.8
45
106
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.6
12.7
101
443
M54.1
ICD-10 Finland
Radiculopathy
5.5
12.6
37
72
M79.6
ICD-10 Finland
Pain in limb
2.1
12.4
193
1168
A28
ICPC
Limited function/disability NOS
2.7
12.4
91
381
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.7
12.3
54
157
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.6
11.8
97
432
N06AX21
ATC
duloxetine; oral
3.1
11.7
69
249
TPH04
NOMESCO Finland
Cathetrisation of vein
2.3
11.6
122
616
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.7
11.5
86
361
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.9
11.4
74
287
N18
ICPC
Paralysis/weakness
9.2
11.4
23
26
N06AX11
ATC
mirtazapine; oral
2.1
11.3
165
962
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.3
11.3
116
579
WX408
NOMESCO Finland
General anesthesy, balanced
2.2
11.2
145
805
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
10.4
11.1
21
21
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
3.5
11.0
52
161
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.4
11.0
55
178
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
6.7
11.0
27
42
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.3
10.9
56
185
M54.9
ICD-10 Finland
Dorsalgia, unspecified
2.9
10.9
69
261
WX892
NOMESCO Finland
Monitored bed care
3.4
10.9
54
174
R06.0
ICD-10 Finland
Dyspnoea
2.2
10.9
136
744
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.9
10.7
219
1453
T36
ICD-10 Finland
Poisoning by systemic antibiotics
4.7
10.5
35
79
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.9
9.9
226
1545
N06AX16
ATC
venlafaxine; oral
2.5
9.8
80
354
N05AH04
ATC
quetiapine; oral
2.4
9.7
93
444
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
5.3
9.7
29
58
B01AB05
ATC
enoxaparin; parenteral
2.0
9.7
160
970
G82.1
ICD-10 Finland
Spastic paraplegia
+∞
9.4
9
*
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
5.6
9.2
26
49
J45.0
ICD-10 Finland
Predominantly allergic asthma
3.0
9.1
52
185
R42
ICD-10 Finland
Dizziness and giddiness
2.1
9.1
115
626
ZX120
NOMESCO Finland
Intravenous
2.9
9.0
56
211
M03BC01
ATC
orphenadrine (citrate); systemic
2.0
9.0
128
731
L17
ICPC
Foot/toe symptom/complaint
2.0
8.9
134
781
Z71.8
ICD-10 Finland
Other specified counselling
2.0
8.9
121
679
G35
ICD-10 Finland
Multiple sclerosis
11.0
8.8
16
15
XKD06
NOMESCO Finland
Physiologic investigation of micturition
5.0
8.8
27
56
NA1AD
NOMESCO Finland
Cervical spine CT examination
4.3
8.8
31
75
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.9
8.7
177
1146
X59
ICD-10 Finland
Exposure to unspecified factor
2.2
8.6
95
487
G44.2
ICD-10 Finland
Tension-type headache
2.4
8.5
76
349
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
5.0
8.5
26
54
J01MA02
ATC
ciprofloxacin; systemic
1.8
8.4
197
1336
M48.0
ICD-10 Finland
Spinal stenosis
2.4
8.4
73
331
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.2
8.4
95
492
SPAT1229
SPAT
Assessment of need for aid
2.9
8.3
51
188
X57
ICD-10 Finland
Unspecified privation
6.7
8.3
20
31
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
2.4
8.2
70
315
C03CA01
ATC
furosemide; systemic
1.9
8.2
140
849
S06.0
ICD-10 Finland
Concussion
2.7
8.2
58
235
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
12.0
8.1
14
12
RS220
NOMESCO Finland
NA
10.3
8.1
15
15
WX110
NOMESCO Finland
Local anesthesy
1.8
8.0
321
2560
N03AX11
ATC
topiramate; oral
5.6
7.9
22
41
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.9
7.9
144
895
C07AB07
ATC
bisoprolol; oral
1.7
7.9
220
1568
H02AB06
ATC
prednisolone; systemic
1.7
7.8
224
1608
N28
ICPC
Limited function/disability (N)
6.1
7.8
20
34
N05BA01
ATC
diazepam; systemic, rectal
2.3
7.7
76
369
G56.2
ICD-10 Finland
Lesion of ulnar nerve
4.4
7.6
26
61
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
5.9
7.6
20
35
N17
ICPC
Vertigo/dizziness
2.5
7.6
60
259
L86
ICPC
Back syndrome with radiating pain
3.2
7.5
38
125
Z01.8
ICD-10 Finland
Other specified special examinations
2.0
7.5
111
636
N02AJ06
ATC
codeine and paracetamol; systemic
1.8
7.5
175
1177
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
2.9
7.4
43
156
NE1AA
NOMESCO Finland
Pelvis X-ray examination
3.2
7.3
37
122
M54.2
ICD-10 Finland
Cervicalgia
2.9
7.3
44
164
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.5
7.3
57
247
N03AX09
ATC
lamotrigine; oral
3.6
7.2
31
90
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
3.1
7.2
38
129
R20.1
ICD-10 Finland
Hypoaesthesia of skin
30.5
7.2
9
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.9
7.2
115
681
N86
ICPC
Multiple sclerosis
20.4
7.2
10
5
X58
ICD-10 Finland
Exposure to other specified factors
2.2
7.1
74
366
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.3
7.1
65
303
H53.1
ICD-10 Finland
Subjective visual disturbances
3.0
7.1
40
141
S13.4
ICD-10 Finland
Sprain and strain of cervical spine
4.4
7.0
24
57
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
2.7
6.9
47
185
B01AC30
ATC
platelet aggregation inhibitors excl. heparin - combinations
2.9
6.9
40
145
R50.9
ICD-10 Finland
Fever, unspecified
2.2
6.9
73
366
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.1
6.9
83
440
A01
ICPC
Pain general/multiple sites
2.7
6.9
47
188
M03BX02
ATC
tizanidine; oral
1.7
6.8
284
2237
PA6AG
NOMESCO Finland
Limited MRI examination of neck vasculature with high intensity magnet
17.0
6.8
10
6
RS221
NOMESCO Finland
NA
7.3
6.7
15
21
W10
ICD-10 Finland
Fall on and from stairs and steps
3.4
6.7
31
96
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.4
6.7
58
264
W00
ICD-10 Finland
Fall on same level involving ice and snow
2.4
6.7
58
264
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.2
6.7
67
325
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
22.9
6.7
9
*
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
4.2
6.7
24
60
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
4.0
6.7
25
65
R07.4
ICD-10 Finland
Chest pain, unspecified
1.8
6.7
138
887
XA800
NOMESCO Finland
Neuropsychological investigation
3.4
6.6
30
92
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.6
6.5
48
199
F43.29
ICD-10 Finland
Adaptation disorder UNS
5.5
6.5
18
34
R33
ICD-10 Finland
Retention of urine
2.7
6.5
43
170
215
Kela drug reimbursment
Diabetes, non-insulin-treated
1.8
6.5
113
686
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
4.8
6.5
20
43
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
3.2
6.5
32
105
R55
ICD-10 Finland
Syncope and collapse
2.3
6.5
61
289
G95.1
ICD-10 Finland
Vascular myelopathies
70.8
6.4
7
*
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
2.5
6.4
48
202
NG4AA
NOMESCO Finland
Lower leg X-ray examination
4.5
6.4
21
48
N06AA09
ATC
amitriptyline; systemic
2.3
6.4
58
269
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
6.7
6.4
15
23
F60.31
ICD-10 Finland
Emotionally unstable personality disorder, borderline condition
8.3
6.4
13
16
109
Kela drug reimbursment
Multiple sclerosis
11.2
6.3
11
10
JN4BD
NOMESCO Finland
Extensive body CT
2.4
6.3
55
250
N02BE01
ATC
paracetamol; systemic, rectal
1.8
6.3
399
3503
P99
ICPC
Psychological disorders other
4.9
6.3
19
40
H53.2
ICD-10 Finland
Diplopia
3.9
6.3
24
64
G83.8
ICD-10 Finland
Other specified paralytic syndromes
+∞
6.3
6
*
PA6BD
NOMESCO Finland
Extensive CT of neck arteries
3.2
6.2
31
102
L01
ICPC
Neck symptom/complaint
2.1
6.2
70
359
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
3.3
6.1
29
93
R53
ICD-10 Finland
Malaise and fatigue
1.9
6.1
100
595
N29
ICPC
Neurological sympt/complt other
5.3
6.1
17
33
M89.0
ICD-10 Finland
Algoneurodystrophy
10.2
6.1
11
11
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
2.9
6.1
35
127
J01DA01
ATC
[U] cefalexin; systemic
1.6
6.0
290
2339
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
257
1276
2.94
32.92
3.0
2.1
200.6
245.2
u/l
0.27
250
1212
161
659
3.06
28.63
7.1
1.8
29.6
29.6
s
0.03
156
641
38
49
8.27
27.99
1.2
1.1
—
—
—
0
0
36
46
8.32
26.69
1.2
1.1
—
—
—
0
0
28
26
11.31
26.19
1.1
1.0
—
—
—
0
0
315
1910
2.57
24.96
6.9
5.4
1.2
1.2
mmol/l
1.21
292
1741
379
2525
2.70
24.41
6.1
4.4
6.8
6.7
mmol/l
0.26
371
2356
89
288
3.50
22.99
2.5
2.4
—
15.4
—
0
16
32
43
7.85
22.72
1.2
1.1
—
—
—
0
0
82
255
3.61
22.49
1.4
1.3
—
40.6
—
0
17
329
2104
2.45
22.22
7.7
6.4
1.2
1.2
mmol/l
0.07
289
1792
197
1019
2.47
21.18
3.2
2.2
—
—
—
0
0
23
23
10.40
20.39
1.2
1.0
1.5
1.1
u/l
—
9
11
290
1815
2.30
19.73
5.0
4.6
35.1
35.7
g/l
1.05
276
1703
335
2240
2.31
19.28
6.4
6.3
10.1
11.2
umol/l
1.48
319
2128
43
99
4.63
17.65
1.4
1.2
5.8
12.7
e6/l
0.45
35
79
43
99
4.63
17.65
1.4
1.3
286.9
123.8
e6/l
0.29
36
82
252
1547
2.18
17.27
5.0
3.1
—
—
—
0
0
147
723
2.42
17.13
4.2
2.5
1.2
1.0
e6/l
0.26
79
403
208
1189
2.22
16.99
4.7
3.0
0.5
0.5
e6/l
0.16
166
892
70
238
3.23
16.53
1.9
1.6
—
—
—
0
0
19
20
9.81
16.19
1.5
1.2
—
—
—
0
0
20
24
8.62
15.47
1.4
1.1
—
—
—
0
0
350
2510
2.13
15.25
14.0
9.1
4.4
4.1
e9/l
1.90
310
2216
137
687
2.33
15.06
4.7
2.7
3.3
2.4
e6/l
0.53
69
368
104
464
2.54
14.77
6.1
7.2
0.4
1.2
mmol/l
1.28
86
366
136
686
2.31
14.71
2.1
1.9
—
—
—
0
0
81
326
2.75
14.11
2.3
3.2
67.1
67.1
g/l
0.02
74
293
210
1299
2.01
13.20
5.1
3.1
32.5
121.6
e6/l
1.05
165
1002
101
471
2.41
12.94
2.0
1.8
—
—
—
0
0
25
47
5.53
12.88
1.3
1.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
19
27
7.26
12.78
1.4
1.1
—
—
—
0
0
128
664
2.22
12.77
7.0
3.2
0.8
0.8
mmol/l
0.40
115
626
412
3248
2.15
12.65
5.1
4.0
14.1
11.8
mm/h
2.12
388
2991
54
186
3.12
12.42
1.9
2.1
40.8
39.2
u/l
0.24
49
163
106
514
2.32
12.40
6.6
6.2
104.3
103.9
mmol/l
0.35
106
498
110
543
2.29
12.33
8.3
4.8
1.0
1.0
mmol/l
0.02
99
499
259
1752
1.92
12.30
2.3
1.9
89.3
95.3
pmol/l
1.56
149
920
99
476
2.32
11.77
2.1
1.9
—
—
—
0
0
107
535
2.25
11.59
26.8
21.5
1.3
1.3
inr
—
10
74
17
24
7.28
11.48
1.4
1.0
—
—
—
0
0
288
2051
1.87
11.36
4.7
3.9
—
—
—
0
0
141
799
2.04
11.01
6.6
3.5
332.1
251.3
ng/l
0.14
114
606
141
801
2.03
10.92
1.7
1.7
1058.7
1202.5
nmol/l
1.15
108
613
71
308
2.50
10.55
1.8
1.5
—
—
—
0
0
94
464
2.24
10.44
7.3
4.2
253.5
242.3
u/l
0.26
88
442
411
3340
1.98
10.16
9.7
7.5
78.2
77.8
u/l
0.09
399
3124
12
13
9.42
9.90
1.3
1.1
—
—
—
0
0
12
13
9.42
9.90
1.3
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
36
111
3.40
9.90
26.2
2.3
0.3
0.4
u/ml
0.26
16
60
239
1664
1.79
9.64
4.6
3.6
41.7
40.7
ng/l
0.03
176
1160
12
14
8.74
9.38
1.4
1.1
—
—
—
0
0
12
14
8.74
9.38
1.4
1.2
—
—
—
0
0
79
383
2.25
9.12
3.0
2.2
33.3
35.0
u/l
0.12
72
327
15
24
6.40
9.03
1.4
1.2
1.8
1.8
mmol/l
0.03
15
24
247
1767
1.74
8.84
2.7
2.3
74.7
76.8
nmol/l
0.43
224
1580
35
114
3.21
8.83
1.3
1.2
—
—
—
0
0
210
1449
1.74
8.46
3.4
3.3
2.4
2.4
mmol/l
0.20
183
1281
76
382
2.15
8.00
5.3
3.2
1.7
2.1
mmol/l
0.30
67
290
39
144
2.84
7.95
2.0
2.6
2.9
3.1
g/l
0.67
34
112
150
957
1.79
7.84
3.8
1.7
1.2
1.2
mg/l
0.03
117
755
25
71
3.64
7.78
1.5
1.3
108.5
107.0
u/ml
—
6
13
34
118
3.01
7.73
1.4
1.2
—
—
—
0
0
40
156
2.69
7.37
2.0
2.5
—
—
—
0
0
40
156
2.69
7.37
2.0
2.5
7.5
7.5
g/l
0.11
34
115
40
156
2.69
7.37
2.0
2.5
3.8
3.7
g/l
0.19
33
109
24
69
3.59
7.35
1.3
1.2
2.2
2.7
u/ml
—
6
22
30
105
2.97
6.74
1.3
1.1
—
—
—
0
0
10
14
7.26
6.72
1.5
1.1
—
—
—
0
0
25
79
3.27
6.65
1.6
1.3
—
—
—
0
0
277
2152
1.59
6.51
4.6
3.6
0.0
0.0
estimate
0.00
39
403
159
1085
1.66
6.33
2.5
2.0
2.9
3.1
mg/l
0.81
133
930
15
34
4.51
6.27
2.7
1.9
1158.8
681.9
e6/l
—
6
15
190
1359
1.62
6.26
3.2
2.4
56.2
56.9
u/l
0.06
173
1261
124
794
1.73
6.25
2.6
3.0
2.5
2.5
mmol/l
0.86
107
705
30
110
2.83
6.22
3.4
1.6
—
—
—
0
0
17
43
4.05
6.21
1.2
1.1
—
—
—
0
0
17
43
4.05
6.21
1.2
1.1
—
—
—
0
0
184
1311
1.61
6.14
3.9
3.1
8.2
7.6
mmol/l
0.75
160
1099
279
2191
1.57
6.12
4.7
3.7
0.0
0.0
estimate
0.50
39
387
39
165
2.47
6.12
1.2
1.2
0.2
2.4
u/ml
—
5
12
87
506
1.86
6.04
2.0
1.8
1.5
1.5
%
0.15
80
437
276
2167
1.56
6.03
6.6
5.0
0.0
0.0
estimate
0.00
40
403
17
44
3.96
6.03
1.2
1.1
—
—
—
0
0
17
44
3.96
6.03
1.2
1.1
—
—
—
0
0
17
44
3.96
6.03
1.2
1.1
—
—
—
0
0
481
4352
1.99
5.81
26.5
13.6
26.1
22.9
mg/l
1.32
426
3436
116
743
1.72
5.80
1.4
1.3
18.9
37.6
iu/ml
2.78
35
241
99
609
1.77
5.70
2.5
2.2
2.5
2.4
g/l
0.96
94
561
61
321
2.02
5.68
5.7
3.0
255.8
195.5
ng/l
0.32
52
292
81
478
1.82
5.35
2.6
2.6
6.9
8.0
umol/l
0.25
65
411
22
74
3.06
5.32
1.3
1.2
3.0
3.7
u/ml
—
8
34
11
22
5.08
5.28
1.8
2.0
—
—
—
0
0
194
1442
1.54
5.22
4.4
3.3
31.8
31.7
u/l
0.03
187
1374
176
1285
1.55
5.12
4.0
4.0
7.2
9.9
mg/mmol
0.54
116
833
20
65
3.16
5.11
1.0
1.1
—
—
—
0
0
27
106
2.63
4.96
1.3
1.3
—
—
—
0
0
381
3290
1.54
4.88
4.3
3.9
14.7
14.8
pmol/l
0.24
356
2988
155
1117
1.54
4.72
3.3
2.7
2945.2
6104.9
umol/l
0.53
133
968
172
1269
1.52
4.70
4.7
3.0
1221.2
1285.8
ng/l
0.10
160
1079
50
265
1.98
4.58
1.6
1.4
—
—
—
0
0
10
21
4.83
4.55
1.3
1.6
—
—
—
0
0
30
130
2.38
4.51
3.3
3.6
3.7
3.8
mmol/l
1.14
30
118
90
579
1.67
4.38
2.7
2.2
21.0
22.3
%
0.49
82
499
12
31
3.94
4.27
1.4
1.8
—
—
—
0
0
9
13
7.02
4.17
1.0
1.0
1746.7
1607.3
miu/ml
—
9
13
32
149
2.22
4.11
2.4
2.3
—
—
—
0
0
10
23
4.41
4.10
1.3
1.1
—
—
—
0
0
49
269
1.90
4.07
6.0
3.7
0.9
1.9
mmol/l
1.51
36
199
7
7
10.11
4.02
1.7
1.4
—
—
—
0
0
7
7
10.11
4.02
1.7
1.4
—
—
—
0
0
7
7
10.11
4.02
1.7
1.3
—
—
—
0
0
23
95
2.48
3.85
1.2
1.2
—
—
—
0
0
67
412
1.72
3.85
2.1
1.8
354.4
374.7
nmol/l
0.34
60
379
30
140
2.21
3.84
1.5
1.5
0.0
0.1
iu/ml
—
7
27
57
338
1.77
3.72
3.2
2.6
70.3
67.0
ml/min/173m2
0.21
21
144
8
12
6.75
3.68
1.4
1.3
—
—
—
0
0
21
85
2.53
3.67
1.7
1.4
—
—
—
0
0
21
85
2.53
3.67
1.7
1.4
—
—
—
0
0
16
56
2.91
3.66
4.7
3.7
—
4287.8
—
0
6
34
171
2.05
3.62
2.2
1.8
—
—
—
0
0
132
968
1.48
3.60
1.4
1.3
0.7
1.5
u/ml
2.15
31
254
60
366
1.72
3.55
2.9
2.4
7.0
7.7
ug/l
0.11
49
330
39
209
1.93
3.50
2.9
2.3
0.7
0.7
%
0.03
39
204
12
36
3.39
3.49
1.8
1.4
37970.0
25396.9
e6/l
—
5
21
32
160
2.06
3.47
2.4
1.7
—
—
—
0
0
437
3986
1.51
3.47
5.6
4.7
1.9
2.2
mu/l
0.61
409
3636
138
1037
1.44
3.30
1.9
1.5
19.9
21.2
nmol/l
0.50
123
886
29
143
2.09
3.27
3.4
3.2
—
—
—
0
0
7
220
0.31
3.26
1.0
1.5
—
—
—
0
0
39
216
1.87
3.19
2.9
2.3
1.6
1.2
%
1.40
39
216
443
4077
1.49
3.11
21.6
12.6
84.8
81.4
ml/min/173m2
2.41
404
3354
19
81
2.39
3.02
1.5
1.2
—
—
—
0
0
230
1913
1.35
2.96
3.2
2.6
118.1
120.5
ug/l
0.05
207
1767
15
58
2.63
2.89
1.0
1.2
—
—
—
0
0
9
22
4.14
2.89
3.0
2.5
403.8
799.5
u/ml
—
9
22
7
13
5.44
2.87
1.3
1.2
—
—
—
0
0
12
41
2.97
2.87
2.5
2.1
—
—
—
0
0
42
249
1.74
2.78
2.5
3.4
4.5
4.6
pmol/l
0.34
37
216
18
78
2.35
2.77
1.5
1.2
287.3
257.2
u/ml
0.12
12
39
23
111
2.12
2.77
1.3
1.2
15.1
10.0
u/l
0.63
15
92
12
43
2.83
2.66
2.1
2.0
—
—
—
0
0
15
61
2.50
2.64
1.3
1.2
0.5
0.6
nmol/l
0.36
15
55
51
324
1.63
2.63
3.7
3.3
81.5
75.0
ng/l
0.21
45
289
27
142
1.95
2.60
1.6
1.3
44.1
23.7
iu/l
1.41
19
125
20
391
0.49
2.57
2.0
1.6
—
—
—
0
0
18
81
2.26
2.56
1.7
1.4
—
—
—
0
0
27
143
1.94
2.55
2.1
2.0
132.4
5041.3
u/l
—
8
62
324
2875
1.32
2.52
4.2
3.1
51.9
47.9
u/l
0.40
307
2703
97
718
1.43
2.48
1.4
1.3
9.9
13.2
u/ml
0.28
31
284
8
22
3.67
2.37
1.3
1.3
—
—
—
0
0
5
9
5.59
2.22
1.0
1.0
—
—
—
0
0
12
48
2.53
2.20
4.0
3.6
—
—
—
0
0
6
15
4.03
2.04
3.0
1.6
—
—
—
0
0
12
50
2.43
2.04
2.1
1.8
—
—
—
0
0
114
898
1.34
2.01
1.6
1.7
69792063.8
7713560.2
pmol/l
0.42
96
739
73
534
1.42
2.01
9.9
7.0
—
—
—
0
0
9
32
2.84
2.01
20.7
13.0
770.8
855.5
nmol/l
—
9
32
6
16
3.78
1.94
1.2
2.1
—
—
—
0
0
6
16
3.78
1.94
1.2
2.1
—
—
—
0
0
24
136
1.80
1.90
1.5
1.5
—
—
—
0
0
307
2762
1.26
1.89
3.4
3.0
—
—
—
0
0
23
130
1.80
1.84
1.2
1.4
356.5
291.5
ug/g
0.94
14
76
6
17
3.56
1.84
1.2
2.0
—
—
—
0
0
7
23
3.07
1.80
1.1
1.8
—
—
—
0
0
7
23
3.07
1.80
1.1
1.8
—
—
—
0
0
7
23
3.07
1.80
1.1
1.8
—
—
—
0
0
7
23
3.07
1.80
1.1
1.8
—
—
—
0
0
6
18
3.36
1.75
2.2
1.3
—
—
—
0
0
19
103
1.88
1.74
1.8
1.5
—
—
—
0
0
8
30
2.69
1.73
1.4
1.2
—
—
—
0
0
10
42
2.41
1.68
3.0
1.8
—
—
—
0
0
12
55
2.21
1.68
1.4
1.2
—
—
—
0
0
140
1162
1.28
1.68
1.9
1.7
1.6
1.4
mmol/l
1.65
128
968
14
70
2.03
1.60
1.1
1.1
0.3
2.9
u/ml
—
8
29
423
3991
1.28
1.56
6.7
5.7
40.4
39.9
mmol/mol
0.51
402
3717
6
21
2.88
1.51
1.0
1.0
—
—
—
0
0
20
116
1.75
1.50
2.6
1.5
—
—
—
0
0
24
147
1.66
1.50
1.1
1.2
—
—
—
0
0
443
4212
1.29
1.48
5.0
4.5
6.0
6.0
mmol/l
0.60
413
3839
481
4627
1.37
1.47
15.7
10.2
26.7
25.9
u/l
0.37
472
4467
24
148
1.65
1.46
1.1
1.2
—
—
—
0
0
6
22
2.75
1.44
2.8
4.1
93.8
95.2
nmol/l
—
6
22
5
17
2.96
1.36
1.0
1.1
—
—
—
0
0
41
297
1.41
1.25
1.2
1.2
65.1
131.0
iu/ml
0.77
14
118
5
19
2.65
1.22
1.0
1.0
—
—
—
0
0
6
26
2.32
1.19
1.7
1.2
—
—
—
0
0
6
26
2.32
1.19
1.7
1.2
—
—
—
0
0
12
64
1.89
1.19
1.0
1.1
—
—
—
0
0
6
126
0.47
1.18
1.2
1.5
—
—
—
0
0
17
102
1.69
1.17
1.2
1.4
—
—
—
0
0
5
20
2.51
1.15
1.6
1.8
—
—
—
0
0
5
20
2.51
1.15
1.6
1.8
—
—
—
0
0
116
987
1.22
1.11
5.4
3.8
1.0
1.0
kg/l
0.39
14
136
8
41
1.97
1.09
1.1
1.8
—
—
—
0
0
8
41
1.97
1.09
1.1
1.8
—
—
—
0
0
8
41
1.97
1.09
1.1
1.8
—
—
—
0
0
56
438
1.31
1.08
3.8
3.2
—
—
—
0
0
135
1171
1.20
1.07
5.3
3.8
0.0
0.0
estimate
0.50
38
397
7
33
2.14
1.06
1.1
1.0
—
—
—
0
0
9
46
1.97
1.04
1.6
1.8
24.1
16.0
ug/l
—
9
46
9
47
1.93
1.02
2.2
3.4
2.3
3.8
nmol/l
—
9
47
9
48
1.89
1.01
1.1
1.1
—
—
—
0
0
7
35
2.01
1.00
1.3
1.2
—
—
—
0
0
17
108
1.59
0.97
1.3
1.8
3.1
5.6
iu/l
—
5
31
7
36
1.96
0.97
1.1
1.3
152.3
287.4
u/l
—
7
36
6
118
0.50
0.95
1.0
1.4
—
—
—
0
0
6
118
0.50
0.95
1.0
1.4
—
—
—
0
0
6
118
0.50
0.95
1.0
1.4
—
—
—
0
0
6
118
0.50
0.95
1.0
1.4
—
—
—
0
0
17
109
1.58
0.94
2.0
1.8
—
—
—
0
0
7
37
1.90
0.94
1.1
1.1
—
—
—
0
0
6
27
2.24
0.93
1.3
1.4
—
—
—
0
0
10
55
1.83
0.92
1.6
2.9
29.2
22.8
mg/l
—
5
18
10
56
1.80
0.88
2.0
2.2
3.5
75.9
u/ml
—
10
51
187
1696
1.16
0.86
5.0
3.8
—
—
—
0
0
6
31
1.95
0.84
1.0
1.3
—
—
—
0
0
30
223
1.37
0.83
1.0
1.0
—
—
—
0
0
6
32
1.88
0.82
1.5
1.8
—
—
—
0
0
413
4270
0.86
0.76
5.1
4.3
1.4
1.5
mmol/l
5.86
389
3939
12
75
1.61
0.75
1.8
1.9
—
—
—
0
0
5
24
2.09
0.74
2.8
2.0
—
—
—
0
0
10
60
1.68
0.72
1.1
1.4
—
—
—
0
0
10
61
1.65
0.69
1.1
1.4
—
—
—
0
0
10
61
1.65
0.69
1.1
1.4
—
—
—
0
0
10
62
1.62
0.65
1.1
1.4
—
—
—
0
0
10
62
1.62
0.65
1.1
1.4
—
—
—
0
0
10
62
1.62
0.65
1.1
1.4
—
—
—
0
0
89
784
1.16
0.61
1.9
1.5
—
—
—
0
0
0
20
0.00
0.60
0.0
1.7
—
—
—
0
0
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
15
106
1.43
0.58
2.2
1.8
—
—
—
0
0
12
82
1.47
0.54
1.9
1.6
—
—
—
0
0
10
66
1.52
0.53
1.3
1.3
—
—
—
0
0
6
41
1.47
0.50
1.8
2.7
—
—
—
0
0
418
4284
0.89
0.50
5.2
4.4
4.5
4.7
mmol/l
3.91
395
3972
10
67
1.50
0.50
1.6
1.8
—
—
—
0
0
52
449
1.18
0.48
3.1
4.4
4.6
30.8
ug/l
0.88
41
383
10
68
1.48
0.47
1.4
1.5
—
—
—
0
0
7
50
1.41
0.45
2.1
1.9
—
—
—
0
0
10
70
1.44
0.42
1.4
1.6
—
—
—
0
0
13
96
1.36
0.42
1.4
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
3.2
—
216.9
—
0
15
8
59
1.36
0.41
2.0
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
87
794
1.11
0.38
2.6
2.9
0.7
0.8
ug/l
0.55
62
512
5
36
1.39
0.38
1.0
1.1
—
—
—
0
0
14
107
1.32
0.37
1.4
1.3
—
—
—
0
0
9
126
0.71
0.35
1.4
1.4
—
—
—
0
0
28
239
1.18
0.32
1.3
1.3
—
—
—
0
0
7
56
1.25
0.29
1.0
1.1
—
—
—
0
0
8
62
1.29
0.28
1.5
1.7
—
—
—
0
0
5
39
1.28
0.23
7.8
3.1
35.5
56.7
u/ml
—
5
39
407
4126
0.94
0.20
4.6
3.9
1.4
1.3
mmol/l
3.30
380
3789
433
4378
0.94
0.18
5.6
4.9
2.6
2.7
mmol/l
2.38
408
4032
8
68
1.18
0.16
1.0
1.1
—
—
—
0
0
17
149
1.15
0.16
1.2
1.9
—
—
—
0
0
401
3964
1.05
0.15
31.7
14.4
38.8
39.9
%
1.78
311
2878
16
181
0.88
0.14
2.7
1.7
3.5
3.4
mg/l
0.01
11
132
58
550
1.06
0.13
4.6
4.4
32.0
32.1
%
0.02
43
364
29
267
1.09
0.13
2.1
1.9
—
—
—
0
0
53
505
1.05
0.11
2.1
2.1
—
—
—
0
0
107
1102
0.96
0.10
3.4
4.3
20.0
21.1
%
0.38
47
505
25
232
1.08
0.10
4.8
2.9
0.3
0.2
e6/l
0.39
25
226
136
1380
0.98
0.05
4.1
4.8
2.2
2.6
ug/l
0.55
123
1233
47
458
1.03
0.03
2.0
1.9
—
—
—
0
0
13
122
1.07
0.02
1.4
1.4
—
—
—
0
0
22
215
1.02
0.00
1.6
1.8
—
—
—
0
0
11
113
0.97
0.00
1.3
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
6
63
0.95
0.00
3.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
67
670
1.00
0.00
1.7
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
24.2
—
0
9
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
3.5
—
83.7
—
0
8
Mortality – FinRegistry
↥Association
Association between endpoint G6_MONOPLE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MONOPLE | 2.189 [1.82, 2.63] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.326 |
During the follow-up period (1.1.1998 — 31.12.2019), 462 out of 1605 females with G6_MONOPLE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MONOPLE | 2.165 [1.83, 2.56] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 563 out of 1664 males with G6_MONOPLE died.
Mortality risk
Mortality risk for people of age
years, who have G6_MONOPLE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.199% | 0.476% |
| 5 | 1.338% | 2.423% |
| 10 | 3.21% | 5.915% |
| 15 | 6.149% | 11.001% |
| 20 | 10.489% | 18.359% |
Relationships between endpoints
↥Index endpoint: G6_MONOPLE – Monoplegia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data